A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 673 participants.
Also called NCT06200207
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 673 participants
- Sponsor
- Registry
-
NCT06200207
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Bulgaria, Canada, Czechia, France, Germany, Greece, India, Malaysia, Poland, Portugal, Spain, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06200207. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2026-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
- Acronym
- ATHENA
- Condition
- Heart Failure
- Condition
- Systemic Inflammation
- Intervention (Drug)
- Ziltivekimab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06200207- Content hash
e810a2a01aa734979cb2dda6b1694841a574240f3a120951f17ea477fe4a00dd